Dutch food and nutrition group Royal Numico has announced that an agreement in principle has been reached to sell its subsidiaries Biodermal and Galenco, including the related production facility in Belgium, to Omega Pharma (Belgium).

The combined sales of the two subsidiaries, which are specialised in skincare products, amounted to approximately €15m (US$15.8m) in 2002.

It is expected that the sale will be finalised by the end of March 2003.

Numico has said that these divestments are in line with the strategic review of the company as announced in November 2002, whereby the company will focus on its core activities baby food and clinical nutrition.